BETHESDA, Md., Nov. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the Board of Directors of the Company appointed Joseph P. Slattery as a member of the Board and as chairman of its audit committee. The appointment will be effective as of November 16, 2007. Mr. Slattery replaces Phillip Schneider who resigned as a member of the Board and as chairman of the audit committee, effective as of the same date. The number of Board members remains unchanged at nine members.
"We welcome Joe Slattery to our Board of Directors," commented Christian Itin, President and Chief Executive Officer, and a member of Micromet's Board. "Joe's financial and industry experience will be invaluable in continuing the high standard for oversight over the financial affairs of Micromet that was set by Phil Schneider. We thank Phil for his service and contributions to the Board and the Company."
"We would like to thank Phil Schneider for his support and guidance during the integration process following the merger between CancerVax and Micromet in May of last year," said David F. Hale, Chairman of Micromet's Board of Directors. "With Joe Slattery, we have an accomplished financial expert with recent operational experience, which enhances the skills and resources already represented on our Board."
Mr. Slattery was Senior Vice President and Chief Financial Officer of
Digene Corporation, and left that position following the acquisition of
Digene by Qiagen in July 2007. He had joined Digene in 1996 as its
Controller prior to its initial pu
|SOURCE Micromet, Inc.|
Copyright©2007 PR Newswire.
All rights reserved